NEW YORK (GenomeWeb) – The University of Texas Southwestern Medical Center has exclusively licensed an exosome-based diagnostic technology to Peregrine Pharmaceuticals.

Financial and other terms of the agreement were not disclosed.

Peregrine VP of Preclinical Research Jeff Hutchins said in a statement that the technology could be used as a companion diagnostic in the development of the firm's lead cancer immunotherapy candidate bavituximab, as well as a more general test for cancer detection and monitoring.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.